Neurochemistry

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Hayward Expands Energy Efficient DOE Compliant Pool Pump Offerings Adding High Performance XE Series Line

Retrieved on: 
Monday, July 12, 2021
Retail, Other Professional Services, Entertainment, Utilities, Consulting, Other Construction & Property, Home Goods, Residential Building & Real Estate, Energy, Commercial Building & Real Estate, General Entertainment, Professional services, Construction & Property, REIT, Chemistry, Physical sciences, Pump, Xe, Neurochemistry

Not only do all XE Series pumps exceed the upcoming benchmarks required by DOE regulations, they also surpass many competitive variable-speed pumps in overall efficiency.

Key Points: 
  • Not only do all XE Series pumps exceed the upcoming benchmarks required by DOE regulations, they also surpass many competitive variable-speed pumps in overall efficiency.
  • The XE Series launch is the latest result of Haywards energy efficiency conversion strategy to deliver market leading, energy efficient products.
  • XE Series pumps take advantage of leading innovation to achieve high levels of efficiency at a more competitive price point.
  • Like all products in Haywards trade-exclusive Expert Line, XE Series pumps are only available from pool professionals.

Beware of Delta-8 Scams: Free Trial, Cheap Knock-Offs & Fake Endorsements, Explained By Vapor Vanity

Retrieved on: 
Thursday, July 8, 2021
Drugs, Cannabinoids, Psychoactive drugs, Business process, Marketing, Delta-8-Tetrahydrocannabinol, Tetrahydrocannabinol, Neurochemistry

The Free Trial Scam: Offering prospective buyers a free trial of a product to convince them of their product's value.

Key Points: 
  • The Free Trial Scam: Offering prospective buyers a free trial of a product to convince them of their product's value.
  • Unfortunately, this great marketing strategy is currently being misused by certain unscrupulous brandsof Delta 8 THC.
  • The Delta 8 free product is discounted at $0, but they pay between $1-10 as a shipping fee with thecredit card.
  • Avoid brandsthat offer free trial versions of their products and follow the buying guide by trusted sources before buying any Delta-8 product.

Los Angeles Says: Too Much Alcohol on These Streets!

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Neurochemistry, Branches of biology, Alcohol, Teratogens, Alcohol powder, Alcohol and health

Our communities are recovering from the most severe health crisis of our time, expansion of alcohol consumption should not be our priority.

Key Points: 
  • Our communities are recovering from the most severe health crisis of our time, expansion of alcohol consumption should not be our priority.
  • Problems from excessive alcohol consumption annually cost approximately $940 for every resident, or $2.44 for every drink.
  • There are already numerous methods for consumers to acquire alcohol in person at retail outlets or through delivery from retailers.
  • The California Alcohol Policy Alliance (CAPA) unites diverse organizations and communities in California to protect health and safety, and prevent alcohol-related harm through statewide action.

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders

Retrieved on: 
Wednesday, July 7, 2021
Chemistry, Physical sciences, Xenon, Neurology, Neurological disorder, Neurochemistry

XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.

Key Points: 
  • XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.
  • Patient randomization has been completed, and topline data are anticipated in late September to mid-October 2021.
  • We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Drugs, Thalmann, Tetrahydrocannabinol, Ladenburg, Cannabinoid, Psychoactive drugs, Neurochemistry

DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m.

Key Points: 
  • DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Ladenburg Thalmann conference coordinator.
  • A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Sleep disorders, Branches of biology, Neurochemistry, Narcolepsy, Sodium oxybate, Cataplexy, gamma-Hydroxybutyric acid, Excessive daytime sleepiness, Food and Drug Administration, Idiopathic hypersomnia

ET.

Key Points: 
  • ET.
  • A live webcast of this event, as well as an archived recording, will be available on Avadels Investor Relations website, www.investors.avadel.com , for 90 days following the conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
  • For more information, please visit www.avadel.com .

Ketamine One Announces Adam Deffett as Interim CEO

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketamine, Ketones, Sedatives

Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.

Key Points: 
  • Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.
  • Ketamine One has launched on a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
  • I would like to thank Robert for stewarding the transition of the Company from an investment issuer under the name of Myconic Capital Corp. to a company dedicated to mental healthcare and the rebrand to Ketamine One, said Adam Deffett, Interim CEO of Ketamine One.
  • Adam Deffett is a senior capital markets professional with over 15 years of experience in the Canadian equity markets.

Strongest Delta-8 THC Gummies Line Launched By BudPop

Retrieved on: 
Tuesday, July 6, 2021
Cannabinoids, Drugs, Psychoactive drugs, Delta-8-Tetrahydrocannabinol, Gummy candy, Tetrahydrocannabinol, Goody, Neurochemistry

Keeping in line with their reputation, they have now come forward with a brand-new line of strongest Delta-8 gummies .

Key Points: 
  • Keeping in line with their reputation, they have now come forward with a brand-new line of strongest Delta-8 gummies .
  • Euphoria-inducing, scrumptious, and infused with the goody-two shoes sister of Delta-9 THC Delta-8 these gummies have enabled BudPop to knock their competition out of the park.
  • The gummies are highly potent and induce a smoother, more relaxing effect than products which use Delta-9 THC.
  • Delta-8 products, especially gummies, are becoming insanely popular as of late, and BudPop is among the top brands in the space.

LED Now Dominant Light Source in Automotive Lighting, says Strategy Analytics

Retrieved on: 
Tuesday, July 6, 2021
Semiconductor, Automotive, Automotive Manufacturing, General Automotive, Technology, Manufacturing, Hardware, Chemistry, Physical sciences, Headlamp, Xenon, Light-emitting diode, Neurochemistry, Automotive lighting

from the Strategy Analytics Powertrain, Body, Safety & Chassis Service ( PBCS ) service, predicts that OEM requirements for styling and functionality will further increase demand for LED-based automotive lighting systems.

Key Points: 
  • from the Strategy Analytics Powertrain, Body, Safety & Chassis Service ( PBCS ) service, predicts that OEM requirements for styling and functionality will further increase demand for LED-based automotive lighting systems.
  • LED has seen further developments in efficiency and Tier 1 vendors have developed cost effective solutions for LED headlight modules.
  • With the urgency to improve efficiency to support emissions and fuel economy mandates, the transition from halogen and xenon to LED has increased.
  • Strategy Analytics, Inc. is a global leader in supporting companies across their planning lifecycle through a range of customized market research solutions.